home All News open_in_new Full Article

2026, el año en que las pastillas contra la obesidad toman protagonismo: de Novo Nordisk a Lilly o Structure Therapeutics

Más de ocho compañías están trabajando en terapias orales. Más información:La FDA aprueba la primera píldora oral contra la obesidad de Novo Nordisk que ya coge ventaja a Lilly


today 26 h. ago attach_file Politics

attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics


ID: 1290235512
Add Watch Country

arrow_drop_down